T1	HMM 27 35	mesylate
T2	HMM 97 129	gastrointestinal stromal tumors.
T3	HMM 276 293	imatinib mesylate
T4	HMM 572 580	imatinib
T5	HMM 845 851	Cancer
T6	HMM 893 901	Oncology
T7	HMM 956 964	imatinib
T8	HMM 984 993	imatinib.
T9	HMM 1191 1199	imatinib
T10	HMM 1287 1295	imatinib
T11	HMM 1313 1343	progression-free survival time
T12	HMM 1550 1559	median OS
T13	HMM 1614 1634	adverse events (AEs)
T14	HMM 1657 1726	nausea, fatigue, skin rash, gastrointestinal complaints, and myalgia.
T15	HMM 1754 1777	abnormality was anemia.
T16	HMM 1793 1796	AEs
